These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30947577)

  • 1. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
    Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
    Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
    Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
    Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
    Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
    Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
    Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
    Li C; Li W; Xu G; You M; Wu W; Kuang L
    Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
    Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
    Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
    Tomita N; Suzuki T; Miyashita K; Yamamoto W; Motohashi K; Tachibana T; Takasaki H; Kawasaki R; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Taguchi J; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Motomura S; Kawamoto K; Sone H; Takizawa J
    Leuk Lymphoma; 2016 Dec; 57(12):2763-2770. PubMed ID: 27320054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial.
    Rizky D; Tandarto K; Pangarsa EA; Naibaho RM; Kurniawan SP; Santosa D; Setiawan B; Suharti C
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1315-1324. PubMed ID: 38679992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
    Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
    Janik JE; Morris JC; Pittaluga S; McDonald K; Raffeld M; Jaffe ES; Grant N; Gutierrez M; Waldmann TA; Wilson WH
    Blood; 2004 Nov; 104(10):3355-7. PubMed ID: 15205267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
    Umino K; Fujiwara SI; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Lymphoma; 2017 Feb; 58(2):316-323. PubMed ID: 27267694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma.
    Dlouhy I; Filella X; Rovira J; Magnano L; Rivas-Delgado A; Baumann T; Martínez-Trillos A; Balagué O; Martínez A; González-Farre B; Karube K; Gine E; Delgado J; Campo E; López-Guillermo A
    Leuk Res; 2017 Aug; 59():20-25. PubMed ID: 28544905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
    Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
    Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
    Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
    Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.